Advertisement

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Peter Clark, MA, MD, FRCP: A Payer Perspective

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Advertisement

Advertisement

Oct

05

Today In Oncology

Wildfire-Related Fine Particulate Matter Linked to Higher Mortality in Older Patients With Lung Cancer

Global Gaps in Cancer-Control Expenditure Data Identified

Autonomous AI Triaged Urgent Suspected Skin Cancer Referrals in Real-World Implementation Study

ER-Positive HER2-Negative Advanced Breast Cancer: Giredestrant Plus Everolimus

FDA Approves First-Line Pirtobrutinib for CLL-SLL

Advertisement

© 2026 HSP News Service, L.L.C.